Selecta has invested substantially in its intellectual property. At its founding, Selecta in-licensed a portfolio of 17 groundbreaking foundational inventions on an exclusive and worldwide basis from MIT, Brigham and Women's Hospital, and Harvard Medical School. Following that, Selecta has continued to build its platform and product-related intellectual property. Our tolerogenic SVP immunotherapies are covered by more than 170 filed and issued patents and more than 7500 claims and our stimulatory vaccines by more than 220 filed or issued patents and more than 9000 claims. We continue to follow a strategy of filing aggressively on our cutting edge technologies in order to lock in our pioneering advantages. In addition to Selecta's comprehensive patent estate, the company also has significant proprietary know-how related to the processes that best enable self-assembling of targeted vaccines and large scale manufacturing.